Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Rivaroxaban tied to higher GI bleeding than other NOACs

Key clinical point: Compared with apixaban and dabigatran, rivaroxaban may cause greater variance in plasma drug concentration, which may make patients more susceptible to bleeding.

Major finding: Patients in the rivaroxaban group had significantly higher rates of GI bleeding, compared with those in the group receiving either apixaban or dabigatran (1.2 vs. 0.6 events per 100 patient-years, respectively).

Study details: A population-based study that compared 4-year GI bleeding rates of 2,635 patients who received rivaroxaban with 2,365 patients who received either apixaban or dabigatran.

Disclosures: The researchers reported having no financial disclosures.